Synonyms: ARQ-151/Zoryve® (roflumilast cream) | BY-217 | BYK-20869 | Daliresp® | Daxas®
roflumilast is an approved drug (EMA (2010), FDA (2011))
Compound class:
Synthetic organic
Comment: Roflumilast is a phosphodiesterase-4 inhibitor.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: roflumilast |
|
References |
1. Huang Z, Mancini JA. (2006)
Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD. Curr Med Chem, 13 (27): 3253-62. [PMID:17168849] |
2. Lebwohl MG, Papp KA, Stein Gold L, Gooderham MJ, Kircik LH, Draelos ZD, Kempers SE, Zirwas M, Smith K, Osborne DW et al.. (2020)
Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med, 383 (3): 229-239. [PMID:32668113] |
3. Lunniss CJ, Cooper AW, Eldred CD, Kranz M, Lindvall M, Lucas FS, Neu M, Preston AG, Ranshaw LE, Redgrave AJ et al.. (2009)
Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration. Bioorg Med Chem Lett, 19 (5): 1380-5. [PMID:19195882] |